vs
Side-by-side financial comparison of Citi Trends Inc (CTRN) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Citi Trends Inc is the larger business by last-quarter revenue ($197.1M vs $103.7M, roughly 1.9× Twist Bioscience Corp). Citi Trends Inc runs the higher net margin — -3.5% vs -29.4%, a 25.9% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 10.1%). Citi Trends Inc produced more free cash flow last quarter ($767.0K vs $-34.8M).
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
CTRN vs TWST — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $197.1M | $103.7M |
| Net Profit | $-6.9M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -3.7% | -31.7% |
| Net Margin | -3.5% | -29.4% |
| Revenue YoY | 10.1% | 16.9% |
| Net Profit YoY | 3.6% | 3.4% |
| EPS (diluted) | $-0.86 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.1M | $103.7M | ||
| Q3 25 | $190.8M | — | ||
| Q2 25 | $201.7M | — | ||
| Q1 25 | $211.2M | — | ||
| Q4 24 | $179.1M | — | ||
| Q3 24 | $176.6M | — | ||
| Q2 24 | $186.3M | — | ||
| Q1 24 | $215.2M | — |
| Q4 25 | $-6.9M | $-30.5M | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $871.0K | — | ||
| Q1 25 | $-14.2M | — | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $-18.4M | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -3.7% | -31.7% | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | -4.9% | — | ||
| Q3 24 | -14.1% | — | ||
| Q2 24 | -3.7% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | -3.5% | -29.4% | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | -6.7% | — | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -10.4% | — | ||
| Q2 24 | -1.8% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | $-0.86 | $-0.50 | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.11 | — | ||
| Q1 25 | $-1.70 | — | ||
| Q4 24 | $-0.86 | — | ||
| Q3 24 | $-2.21 | — | ||
| Q2 24 | $-0.42 | — | ||
| Q1 24 | $0.43 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $107.8M | $456.1M |
| Total Assets | $464.3M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $107.8M | $456.1M | ||
| Q3 25 | $113.2M | — | ||
| Q2 25 | $108.6M | — | ||
| Q1 25 | $113.2M | — | ||
| Q4 24 | $130.3M | — | ||
| Q3 24 | $136.6M | — | ||
| Q2 24 | $154.8M | — | ||
| Q1 24 | $157.7M | — |
| Q4 25 | $464.3M | $638.1M | ||
| Q3 25 | $457.4M | — | ||
| Q2 25 | $437.4M | — | ||
| Q1 25 | $462.8M | — | ||
| Q4 24 | $467.1M | — | ||
| Q3 24 | $506.7M | — | ||
| Q2 24 | $484.1M | — | ||
| Q1 24 | $518.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.6M | $-24.8M |
| Free Cash FlowOCF − Capex | $767.0K | $-34.8M |
| FCF MarginFCF / Revenue | 0.4% | -33.5% |
| Capex IntensityCapex / Revenue | 4.0% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $11.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | $-24.8M | ||
| Q3 25 | $3.9M | — | ||
| Q2 25 | $-11.0M | — | ||
| Q1 25 | $28.5M | — | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $5.6M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $23.3M | — |
| Q4 25 | $767.0K | $-34.8M | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $26.0M | — | ||
| Q4 24 | $-20.4M | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $-21.2M | — | ||
| Q1 24 | $20.0M | — |
| Q4 25 | 0.4% | -33.5% | ||
| Q3 25 | -0.9% | — | ||
| Q2 25 | -6.5% | — | ||
| Q1 25 | 12.3% | — | ||
| Q4 24 | -11.4% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | -11.4% | — | ||
| Q1 24 | 9.3% | — |
| Q4 25 | 4.0% | 9.6% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRN
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
